Analyst Expectations for Neurocrine Biosciences's Future
Portfolio Pulse from Benzinga Insights
Over the past 3 months, 17 Wall Street analysts have published their opinions on Neurocrine Biosciences (NASDAQ:NBIX), with the majority being bullish or somewhat bullish. The average 12-month price target for NBIX is $130.0, with a high of $165.00 and a low of $100.00, marking a 4.84% increase from the previous target of $124.00. Analysts rate stocks based on company financials, meetings, and insider communications, typically updating their ratings quarterly or after major company events.
December 07, 2023 | 4:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Neurocrine Biosciences has received a majority of bullish or somewhat bullish ratings from analysts, with an updated average price target of $130.0, suggesting a positive outlook for the stock.
The positive sentiment from analysts, reflected in the majority of bullish ratings and an increased average price target, is likely to instill confidence in investors and could lead to a short-term increase in NBIX's stock price.
CONFIDENCE 80
IMPORTANCE 85
RELEVANCE 100